Onesource Specialty Pharma Limited (NSE: ONESOURCE) and Syngene International Ltd. (NSE: SYNGENE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Onesource Specialty Pharma has a market capitalisation of ₹17,868 Cr and Syngene International ₹16,439 Cr, as of 9 Nov 2026. Return on equity is -1.26% for Onesource Specialty Pharma and 6.62% for Syngene International. Over one year, Onesource Specialty Pharma's share price is down 14.1% and Syngene International's is down 33.7%.
| Metric | Onesource Specialty Pharma | Syngene International |
|---|---|---|
| NSE Symbol | ONESOURCE | SYNGENE |
| BSE Code | 544292 | 539268 |
| Share Price | ₹1,613.50 | ₹436.00 |
| Market Cap | ₹17,868 Cr | ₹16,439 Cr |
| P/E Ratio | Not meaningful (loss) | 52.5 |
| Return on Equity | -1.26% | 6.62% |
| Return on Assets | -0.03% | 4.78% |
| Dividend Yield | — | 0.30% |
| Beta (1Y) | 0.25 | -0.08 |
| 1-Year Price Change | -14.1% | -33.7% |
| 3-Month Price Change | +2.4% | +8.3% |
| 52-Week Range | ₹1,057.00 – ₹1,917.80 | ₹344.45 – ₹678.95 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹516 Cr | ₹833 Cr |
| Quarterly Net Profit | ₹57 Cr | ₹32 Cr |
| Net Margin | 11.1% | 3.9% |
| EPS (Basic, Quarter) | — | ₹0.80 |
| Results Basis | consolidated | consolidated |
| Headquarters | Bengaluru, Karnataka | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoin…
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i…
Onesource Specialty Pharma has a market capitalisation of ₹17,868 Cr, against ₹16,439 Cr for Syngene International as of 9 Nov 2026, so the two are about the same size by market cap.
Onesource Specialty Pharma has a return on equity of -1.26% and Syngene International 6.62%.
Onesource Specialty Pharma's share price is down 14.1% over one year and Syngene International's is down 33.7%.
Onesource Specialty Pharma reported revenue of ₹516 Cr and net profit of ₹57 Cr for Q2 FY27. Syngene International reported revenue of ₹833 Cr and net profit of ₹32 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.